Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOSTON SCIENTIFIC CORPBSX · Entity 1897 | EVP, GC and Corp. Secretary | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOSTON SCIENTIFIC CORP
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,244 |
Ending reported balance
After 2026-02-16 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-02-13 · Grant · Acquired 14,804 · Balance 49,209 F1: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 2 · 2026-02-13 · Grant · Acquired 14,804 · Balance 64,013 F2: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. Row 3 · 2026-02-13 · Exercise / conversion · Acquired 1,118 · Balance 65,131 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 4 · 2026-02-13 · Tax withholding · Disposed 12,792 · Balance 52,339 Row 5 · 2026-02-14 · Exercise / conversion · Acquired 1,851 · Balance 54,190 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 6 · 2026-02-14 · Tax withholding · Disposed 895 · Balance 53,295 Row 7 · 2026-02-16 · Exercise / conversion · Acquired 1,839 · Balance 55,134 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Row 8 · 2026-02-16 · Tax withholding · Disposed 890 · Balance 54,244 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2029-02-13 | Direct | 3,357 |
Reported balance
After 2026-02-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-02-13 · Exercise / conversion · Disposed 1,118 · Balance 3,357 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2027-02-14 | Direct | 1,851 |
Reported balance
After 2026-02-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-14 · Exercise / conversion · Disposed 1,851 · Balance 1,851 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2026-02-16 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-02-16 · Exercise / conversion · Disposed 1,839 · Balance 0 F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F6: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Total Shareholder Return Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Health Care Index over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F2: On February 14, 2023, the reporting person was awarded a target number of performance share units under the Company's 2023 Organic Net Sales Performance Share Program, with the actual number to be earned by the reporting person to be based on the Company's organic net sales performance measured against its financial plan over the three-year performance cycle comprising the three-year period ended December 31, 2025 and subject to the completion of the concurrent three-year individual service period. On February 13, 2026, the number of performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied.
F3: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F4: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 13, 2026, the first anniversary of the date of grant.
F5: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 14, 2024, the first anniversary of the date of grant.
F6: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 214 | $42.55 | $9,105.70 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · nonDerivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,487 Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 741 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · nonDerivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionRestricted Stock Units · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · derivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 1,000 shares Expires 2025-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 17, 2022, the first anniversary of the date of grant. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 332 | $42.83 | $14,219.56 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,960 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 21:43 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002914 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:00 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantStock Option (Right to Buy) · Derivative | 21,029 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · derivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,029 Underlying: Common Stock · 21,029 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:00 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 7,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · derivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,354 Underlying: Common Stock · 7,354 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:00 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923 Underlying: Common Stock · 923 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:00 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 323 | $44.01 | $14,215.23 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,292 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:00 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| October 02, 2021 Filed Oct 4, 2021 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionDeferred Stock Units · Derivative | 3,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-012801 · doc4.xml · derivative · entry 3 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,394 Underlying: Common Stock · 3,393 shares Expires 2022-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on October 2, 2018, the first anniversary of the date of grant. Read SEC document |
| October 02, 2021 Filed Oct 4, 2021 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Tax withholdingCommon Stock | 1,137 | $43.80 | $49,800.60 |
DisclosureSEC source: 0001225208-21-012801 · doc4.xml · nonDerivative · entry 2 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,692 Read SEC document |
| October 02, 2021 Filed Oct 4, 2021 21:32 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | Exercise / conversionCommon Stock | 3,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-012801 · doc4.xml · nonDerivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:08 UTC | BOSTON SCIENTIFIC CORP BSX · Entity 1897 | GrantRestricted Stock Units · Derivative | 16,143 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-010270 · doc4.xml · derivative · entry 1 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,143 Underlying: Common Stock · 16,143 shares Expires 2025-07-01 F1 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common slock will be issued to the reporting person in four equal annual installments beginning on July 1, 2022, the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.